Alpharma's Embeda has improved abuse profile, US panel says
This article was originally published in Scrip
Executive Summary
Alpharma's Embeda (ALO-01), a modified-release formulation of morphine coupled with the opioid antagonist naltrexone, is an incremental improvement over existing morphine products because it appears to be less susceptible to abuse and misuse, the FDA's anaesthetic and life support drugs and drug safety/risk management advisory panels said on November 14th.